Synthesis and characterization of related substances of Azilsartan Kamedoxomil

1. Aulakh G.K., Sodhi R.K., Singh M.: An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. J. Life Sci., 81, 615, 2007.Search in Google Scholar

2. Bansal D. et al.: An improved process for the preparation of azilsartan medoxomil. Patent WO/2012/107814, 2012.Search in Google Scholar

3. Dubey S. K. et al.: Indian patent Appl.No.IN2011DE01901 A 20131004.Search in Google Scholar

4. International Conference on Harmonization (ICH) guidelines. Q2B validation of analytical procedure: Methodology. ICH guidelines: Geneva, Switzerland, November, 1996.Search in Google Scholar

5. International Conference on Harmonization (ICH) guidelines. Q3A (R) impurities in New Drug Substances. ICH guidelines: Geneva, Switzerland, February, 2002.Search in Google Scholar

6. Jo N. et al.: A manufacturing method for azilsartan. Patent WO/2012/157980, 2012.Search in Google Scholar

7. Kohara Y. et al.: A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorg. Med. Chem. Lett., 5, 1903, 1995.10.1016/0960-894X(95)00319-OSearch in Google Scholar

8. Kohara Y. et al.: Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres. J. Med. Chem., 39, 5228, 1996.10.1021/jm960547h8978851Search in Google Scholar

9. Kshirsagar P. B. et al.: The process for the preparation of azilsartanmedoxomil. Patent WO/2013/042066, 2013.Search in Google Scholar

10. Kubo K. et al.: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J. Med. Chem., 36, 2182, 1993.10.1021/jm00067a0168340921Search in Google Scholar

11. Kuroita T. et al.: Compound which is an angiotensin antagonist. U.S. Patent No.7, 157, 584.Search in Google Scholar

12. Miura S., Karnik S.S., Saku K.: Ability of the new AT1 receotir blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J. Renin Angiotensin Aldosterone Syst., 12, 1, 2011.Search in Google Scholar

13. Naka T. K., Inada. Y.: (Takeda Chem. Ind). U.S.Patent No.5, 243, 054.Search in Google Scholar

14. Radl S. et al.: Synthesis of Azilsartan and its selected potential impurities. J. Heterocyclic Chem., 50, 929, 201310.1002/jhet.1783Search in Google Scholar

15. Radl S., Stach J.: A method of preparing 2-ethoxy-1-((2’-(5-oxo-4,5- dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d] imidazole-7-carboxylates and conversion thereof to azilsartan. WO/2012/139535. 2012.Search in Google Scholar

16. Raghavareddy A. V. et al.: A novel process for the preparation of Azilsartan medoxomil. Indian patent App. No. 4226/CHE/2012A.Search in Google Scholar

17. Sangeeta S. et al.: Synthesis and Characterization of Impuritiesof a Common and Advanced Intermediate of Candesartan and Azilsartan Antihypertensive Drugs. Int. Res. J. Pure App. Chem., 5, 140, 2015.10.9734/IRJPAC/2015/13162Search in Google Scholar

18. Sethi M. K. et al.: Related substances of azilsartan medoxomil: synthesis and characterization. Der Pharma Chemica, 7, 20, 2015.Search in Google Scholar

19. Srinivas G. et al.: Commercial synthesis of Azilsartan Kamedoxomil: An angiotensin II receptor blocker. Org. Process Res. Dev., 19, 514, 2015.10.1021/op500357rSearch in Google Scholar

20. Stanislav R. et al.: Improved process for Azilsartan medoxomil: A new angiotensin receptor blocker. Org. Process Res. Dev., 17, 77, 2013.10.1021/op3002867Search in Google Scholar